Sartorius Announces Offer To Acquire TAP Biosystems Group
Sartorius announces offer to acquire TAP Biosystems Group, a UK-based company.
Sartorius Stedim Biotech has made a cash offer to acquire the UK company TAP Biosystems Group (TAP Biosystems) through its wholly owned subsidiary Sartorius Stedim Biotech GmbH. The proposed transaction, which is subject to customary closing conditions, including the approval of TAP’s shareholders, values the equity of TAP Biosystems at approximately $44 million (€33 million). The transaction has been unanimously approved by the boards of directors of both companies and is expected to close at the end of 2013.
TAP Biosystems specializes in the design and development of small-scale, multi-parallel fermentation systems particularly for biopharmaceutical applications. With its ambr-product family, the company has launched a technology for single-use fermentation that is designed to mimic mammalian cell culture at small scale, an alternative to conventional systems.
Source: Sartorius Stedim Biotech
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
